FAS and neoplasm: Strikingly, a single-point mutation in FasL R163A (or E271A) with the inability to form salt-bridges with R87 of Fas rendered both E09-Fasl and EP6-FasL ineffective in tumor cells and tumor xenografts (Fig. 7G–I).